Eaton Vance Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $121M | Sell |
1,157,648
-66,694
| -5% | -$7.32M | 0.18% | 123 |
|
|
2022
Q2 | $129M | Buy |
1,224,342
+48,585
| +4% | +$5.76M | 0.18% | 122 |
|
|
2022
Q1 | $150M | Buy |
1,175,757
+970,165
| +472% | +$117M | 0.17% | 124 |
|
|
2021
Q4 | $25.4M | Sell |
205,592
-307
| -0.1% | -$40.2K | 0.03% | 424 |
|
|
2021
Q3 | $28.8M | Sell |
205,899
-537
| -0.3% | -$79K | 0.04% | 367 |
|
|
2021
Q2 | $32.2M | Buy |
206,436
+2,399
| +1% | +$389K | 0.04% | 364 |
|
|
2021
Q1 | $31.7M | Sell |
204,037
-617
| -0.3% | -$95.6K | 0.05% | 348 |
|
|
2020
Q4 | $30.6M | Buy |
204,654
+1,396
| +0.7% | +$197K | 0.05% | 341 |
|
|
2020
Q3 | $26.9M | Buy |
203,258
+1,580
| +0.8% | +$206K | 0.05% | 310 |
|
|
2020
Q2 | $23.4M | Buy |
201,678
+879
| +0.4% | +$101K | 0.05% | 312 |
|
|
2020
Q1 | $19.7M | Sell |
200,799
-3,522
| -2% | -$462K | 0.05% | 304 |
|
|
2019
Q4 | $29.7M | Buy |
204,321
+2,715
| +1% | +$375K | 0.06% | 270 |
|
|
2019
Q3 | $26.9M | Sell |
201,606
-418
| -0.2% | -$54K | 0.06% | 262 |
|
|
2019
Q2 | $23.1M | Buy |
202,024
+12,351
| +7% | +$1.45M | 0.05% | 284 |
|
|
2019
Q1 | $23.5M | Buy |
189,673
+1,107
| +0.6% | +$126K | 0.05% | 269 |
|
|
2018
Q4 | $19M | Buy |
188,566
+492
| +0.3% | +$55.3K | 0.05% | 267 |
|
|
2018
Q3 | $24M | Sell |
188,074
-595
| -0.3% | -$70.7K | 0.05% | 261 |
|
|
2018
Q2 | $20.4M | Sell |
188,669
-191,601
| -50% | -$20.9M | 0.05% | 275 |
|
|
2018
Q1 | $40.3M | Buy |
380,270
+188,224
| +98% | +$21.9M | 0.05% | 273 |
|
|
2017
Q4 | $22.5M | Sell |
192,046
-186,405
| -49% | -$21.1M | 0.05% | 261 |
|
|
2017
Q3 | $43M | Sell |
378,451
-1,391,679
| -79% | -$161M | 0.11% | 170 |
|
|
2017
Q2 | $221M | Sell |
1,770,130
-118,848
| -6% | -$14.1M | 0.58% | 46 |
|
|
2017
Q1 | $224M | Buy |
1,888,978
+273,877
| +17% | +$31M | 0.6% | 40 |
|
|
2016
Q4 | $162M | Sell |
1,615,101
-611,679
| -27% | -$65.6M | 0.46% | 63 |
|
|
2016
Q3 | $281M | Buy |
2,226,780
+831,049
| +60% | +$103M | 0.81% | 33 |
|
|
2016
Q2 | $163M | Sell |
1,395,731
-180,486
| -11% | -$20.4M | 0.48% | 61 |
|
|
2016
Q1 | $163M | Buy |
1,576,217
+704,201
| +81% | +$68.1M | 0.5% | 58 |
|
|
2015
Q4 | $86.9M | Buy |
872,016
+19,882
| +2% | +$1.95M | 0.26% | 106 |
|
|
2015
Q3 | $77.7M | Buy |
852,134
+681,125
| +398% | +$68.3M | 0.24% | 108 |
|
|
2015
Q2 | $18.1M | Sell |
171,009
-1,303
| -0.8% | -$144K | 0.06% | 246 |
|
|
2015
Q1 | $19.7M | Sell |
172,312
-464
| -0.3% | -$52.9K | 0.06% | 234 |
|
|
2014
Q4 | $19M | Sell |
172,776
-61
| -0% | -$6.43K | 0.06% | 237 |
|
|
2014
Q3 | $16.9M | Sell |
172,837
-1,818
| -1% | -$179K | 0.05% | 240 |
|
|
2014
Q2 | $17.6M | Buy |
174,655
+40,128
| +30% | +$3.92M | 0.05% | 235 |
|
|
2014
Q1 | $12.4M | Sell |
134,527
-418
| -0.3% | -$38.5K | 0.04% | 282 |
|
|
2013
Q4 | $12.2M | Buy |
134,945
+16
| +0% | +$1.39K | 0.04% | 282 |
|
|
2013
Q3 | $10.8M | Buy |
134,929
+37,601
| +39% | +$2.96M | 0.03% | 278 |
|
|
2013
Q2 | $7.08M | Buy |
+97,328
| New | +$7.28M | 0.02% | 312 |
|
Other funds holding ZBH
Eaton Vance Management's ZBH Position: Q3 2022 in Review
Eaton Vance Management reduced its Zimmer Biomet (ZBH) stake by 5.4% in Q3 2022, selling an estimated $7.32M and leaving 1,157,648 shares worth $121M. The position accounts for 0.18% of the portfolio, ranked #123.
Eaton Vance Management first reported a position in ZBH in Q2 2013 and has held it in 38 quarters since. The position peaked at $281M in Q3 2016. 919 funds tracked by Wall St. Rank hold ZBH as of Q3 2022.
- Eaton Vance Management held 1,157,648 shares of Zimmer Biomet worth $121M as of Q3 2022.
- Eaton Vance Management sold 66,694 Zimmer Biomet shares in Q3 2022, an estimated $7.32M.
- Zimmer Biomet made up 0.18% of Eaton Vance Management's portfolio in Q3 2022, its #123 holding.
- Eaton Vance Management first reported a position in Zimmer Biomet in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's Zimmer Biomet position peaked at $281M in Q3 2016.
- 919 funds tracked by Wall St. Rank held Zimmer Biomet as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.